Gene therapy progress and prospects: RNA aptamers

Gene Therapy

Volumn 14, Issue 4, 2007, Pages 283-291

  Que Gewirth, N S ^a   Sullenger, B A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 22; ANTIDOTE; APTAMER; ARC 183; ARC 2127; AS 1411; AVRINA; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; COMPLEMENTARY RNA; DOCETAXEL; EDIFOLIGIDE; HEPARIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NU 172; PEGAPTANIB; PLACEBO; PROTAMINE; RANIBIZUMAB; REG 1; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZANAMIVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATOPIC DERMATITIS; CLINICAL TRIAL; COLON CARCINOMA; DIABETIC MACULAR EDEMA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENTERITIS; EXPRESSION VECTOR; GENE THERAPY; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROSTATE CANCER; PROTEIN TARGETING; RETINA MACULA DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; STROKE; UNSPECIFIED SIDE EFFECT; VEIN GRAFT DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

APTAMERS, NUCLEOTIDE; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; STEM CELL TRANSPLANTATION;

EID: 33846914204     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302900     Document Type: Review

References (73)

1. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: An emerging class of therapeutics. Ann Rev Med 2005; 56: 555-583.
2. Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005; 87: 921-930.
3. Huang DB, Vu D, Cassiday LA, Zimmerman JM, Maher III LJ, Ghosh G. Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer. Proc Natl Acad Sci USA 2003; 100: 9268-9273.
4. Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR, Pendergrast PS et al. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem Biol 2005; 12: 25-33.
5. Vater A, Klussman S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr Opin Drug Dev 2003; 6: 253-261.
6. Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick Jr G et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004; 22: 1423-1428.
7. Healy JM, Lewis SD, Kurz M, Boomer RM, Thompson KM, Wilson C et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 2004; 21: 2234-2246.
8. Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 2003; 63: 7483-7489.
9. Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, Shima DT et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005; 102: 18902-18907.
10. Morishita R. Perspective in progress of cardiovascular gene therapy. J Pharmacol Sci 2004; 95: 1-8.
11. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R. Application of decoy oligodeoxynucleotides-based approach to renal diseases. Curr Drug Targets Infect Disord 2004; 5: 717-733.
12. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson Jr TB, Lorenz TJ et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure followAng coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 2446-2454.
13. Mann MJ. Transcription factor decoys: A new model for disease intervention. Ann N Y Acad Sci 2005; 1058: 128-139.
14. Matsuda N, Hattori Y, Takahashi Y, Nishihira J, Jesmin S, Kobayashi M et al. Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1248-L1255.
15. Ogushi I, Iimuro Y, Seki E, Son G, Hirano T, Hada Tet al. Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model. Hepatology 2003; 38: 335-344.
16. De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T et al. Non-viral' delivery of NF-{kappa}B decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2006, Epub ahead of print.
17. Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 2005; 93: 1014-1020.
18. Pavlov V, Zorn M, Kramer R. Probing single-stranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade. Biochem Biophys Res Commun 2006; 349: 1011-1015.
19. www.archemix.com.
20. www.nuvelo.com.
21. Thiel KA. Oligo oligarchy - the surprisingly small world of aptamers. Nat Biotechnol 2004; 22: 649-651.
22. www.antisoma.com.
23. Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 2006; 5: 1790-1799.
24. Akiyama H, Kachi S, Silva RL, Umeda N, Hackett SF, McCauley D et al. Intraocular injection of an aptamer that binds PDGF-B: A potential treatment for proliferative retinopathies. J Cell Physiol 2006; 207: 407-412.
25. Jeon SH, Kayhan B, Ben-Yedidia T, Arnon R. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J Biol Chem 2004; 279: 48410-48419.
26. First Data Bank. Based on AWP. April 2006. www.firstdatabank.com.
27. www.macular.org/news.
28. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006; 355: 1419-1431.
29. www.agingeye.net/mainnews/lucentis.php.
30. San Francisco Chronicle. San Francisco Chronicle. San Francisco, 2006.
31. www.medicalnewstoday.com.
32. Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 2006; 14: 408-415.
33. Heckel A, Mayer G. Light regulation of aptamer activity: An anti-thrombin aptamer with caged thymidine nucleobases. J Am Chem Soc 2005; 127: 822-823.
34. Mayer G, Krock L, Mikat V, Engeser M, Heckel A. Light-induced formation of G-quadruplex DNA secondary structures. Chem-biochem 2005; 6: 1966-1970.
35. Heckel A, Buff MC, Raddatz MS, Muller J, Potzsch B, Mayer G. An anticoagulant with light-triggered antidote activity. Angew Chem Int Ed Engl 2006; 45: 6748-6750.
36. Held DM, Kissel JD, Patterson JT, Nickens DG, Burke DH. HIV-1 inactivation by nucleic acid aptamers. Front Biosci 2006; 11: 89-112.
37. Choi KH, Park MW, Lee SY, Jeon MY, Kim MY, Lee HK et al. Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol Cancer Ther 2006; 5: 2428-2434.
38. Li MJ, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206.
39. Mi J, Zhang X, Rabbani ZN, Liu Y, Su Z, Vujaskovic Z et al. H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acid Res 2006; 34: 3577-3584.
40. Joshi PJ, Fisher TS, Prasad VR. Anti-HIV inhibitors based on nucleic acids: Emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord 2003; 3: 383-400.
41. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: Novel gene therapy approaches for AIDS. Gene Ther 2005; 12: 467-476.
42. Zhang Z, Blank M, Schluesener HJ. Nucleic acid aptamers in human viral disease. Arch Immunol Ther Exp (Warsz) 2004; 52: 307-315.
43. Michienzi A, Castanotto D, Lee N, Li S, Zaia JA, Rossi JJ. RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci 2003; 1002: 63-71.
44. Nickens DG, Patterson JT, Burke DH. Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli. RNA 2003; 9: 1029-1033.
45. Hannoush RN, Carriero S, Min KL, Damha MJ. Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells. Chembiochem 2004; 5: 527-533.
46. Somasunderam A, Ferguson MR, Rojo DR, Thiviyanathan V, Li X, O'Brien WA et al. Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 2005; 44: 10388-10395.
47. Khati M, Schuman M, Ibrahim J, Sattentau Q, Gordon S, James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 2003; 77: 12692-12698.
48. Dey AK, Khati M, Tang M, Wyatt R, Lea SM, James W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 2005; 79: 13806-13810.
49. Kuwasaki T, Hatta M, Takeuchi H, Takaku H. Inhibition of human immunodeficiency virus 1 replication in vitro by a self-stabilized oligonucleotide with 2′-O-methyl-guanosine-uridine quadruplex motifs. J Antimicrob Chemother 2003; 51: 813-819.
50. Nishikawa F, Kakiuchi N, Funaji K, Fukuda K, Sekiya S, Nishikawa S. Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res 2003; 31: 1935-1943.
51. Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K et al. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure (Cambridge) 2001; 9: 321-329.
52. Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Therapy 2006; 13: 553-558.
53. Bartosch B, Cosset FL. Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther 2004; 4: 427-443.
54. Banerjea A, Li MJ, Remling L, Rossi J, Akkina R. Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res Ther 2004; 1: 2.
55. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
56. Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, Rossi JJ. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res 2003; 23: 1997-2005.
57. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 2004; 64: 7668-7672.
58. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006; 3: 311-324.
59. Chu TC, Marks III JW, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD et al. Aptamer:tOxin conjugates that specifically target prostate tumor cells. Cancer Res 2006; 66: 5989-5992.
60. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34: E73.
61. McNamara II JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24: 1005-1015.
62. Rossi JJ. Partnering aptamer and RNAi technologies. Mol Ther 2006; 14: 461-462.
63. An CI, Trinh VB, Yokobayashi Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA 2006; 12: 710-716.
64. Chan R, Gilbert M, Thompson KM, Marsh HN, Epstein DM, Pendergrast PS. Co-expression of anti-NF-kappaB RNA aptamers and siRNAs leads to maximal suppression of NF-kappaB activity in mammalian cells. Nucleic Acids Res 2006; 34: E36.
65. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 2003; 100: 15416-15421.
66. Fitter S, James R. Deconvolution of a complex target using DNA aptamers. J Biol Chem 2005; 280: 34193-34201.
67. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103: 11838-11843.
68. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005; 3: E123.
69. Blank M, Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol 2005; 9: 336-342.
70. Proske D, Blank M, Buhmann R, Resch A. Aptamers - basic research, drug development, and clinical applications. Appl Microbiol Biotechnol 2005; 69: 367-374.
71. www.clinicaltrials.gov/ct/show/NCT00074997.
72. Russell S. High hopes for AIDS therapy: experimental treatment fortifies the body's own stem cells with an enzyme that could block the virus' relentless advance. San Francisco Chronicle: San Francisco, 2006.
73. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601-2605.